Glucocorticoid receptor–Estrogen receptor alpha interface (GR–ERα interface)

The Glucocorticoid receptor–Estrogen receptor alpha (GR–ERα) interface is a functional and physical interaction site between two key nuclear receptors that regulate gene expression in steroid-responsive tissues. In the context of breast cancer, particularly estrogen receptor-positive (ER+) subtypes, the activation of GR often results in the displacement of ERα from shared chromatin binding sites or the recruitment of co-repressors, thereby inhibiting estrogen-driven proliferative pathways (PubMed: 25915415). This crosstalk makes the interface a significant therapeutic target, as GR agonists like dexamethasone can be used to reprogram the ERα transcriptome and improve clinical outcomes by antagonizing tumor growth (PubMed: 26464293). The interaction involves direct protein-protein binding as well as competition for genomic response elements, which dictates the cellular response to hormonal stimuli. However, the role of this interface is highly context-specific; while it is tumor-suppressive in ER+ breast cancer, GR signaling can promote survival and chemoresistance in triple-negative breast cancer (PubMed: 23934152). Therapeutic strategies focusing on this interface aim to leverage the tumor-suppressive effects of GR while minimizing the systemic side effects associated with chronic glucocorticoid administration.

Other names

GR-ERα crosstalkNR3C1-ESR1 interactionGlucocorticoid receptor-Estrogen receptor alpha complexGR-ERα physical interaction

Agonism of the Glucocorticoid receptor to induce transcriptional interference with Estrogen receptor alpha, leading to the displacement of ERα from DNA and the suppression of estrogen-dependent proliferative genes.